Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998839 | 0.92 | GSK3B (0.34) | GSK3BMAPK14HTR7MCL1FLT3 | |
| SCHEMBL2000118 | 0.86 | KCNH2 (0.33) | GSK3BMAPK14HTR7NPC1MAPT | |
| SCHEMBL1998682 | 0.85 | MAPT (0.35) | HTR7NPC1MAPTMAPK1RAB9A | |
| SCHEMBL2003026 | 0.85 | GSK3B (0.33) | GSK3BMAPK14HTR7MAPTFLT3 | |
| SCHEMBL1998528 | 0.84 | LMNA (0.42) | HTR7NPC1MAPTMAPK1RAB9A | |
| SCHEMBL2001021 | 0.81 | LMNA (0.33) | GSK3BMAPK14MAPTLMNA | |
| SCHEMBL5227650 | 0.79 | SIRT1 (0.35) | NPC1MAPK1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL5226460 | 0.79 | ALDH1A1 (0.38) | NPC1MAPTMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL5228511 | 0.79 | MAPT (0.38) | HTR7NPC1MAPTSMN1; SMN2 | |
| SCHEMBL1994787 | 0.77 | MAPT (0.33) | HTR7NPC1MAPTMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960413-B2 | Pyrazole compounds | MERCK PATENT GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20060276650-A1 | Pyrazole compounds | MERCK PATENT GMBH (DE) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276650-A1 | Pyrazole compounds | HTR1D, HTR1A, HTR3A | GSK3B 2802/4885MAPK14 3554/4885HTR7 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.